Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“At ESMO25 in Berlin, we’re looking forward to presentations across our leading portfolio that showcase our progress in redefining standards of care in multiple challenging-to-treat cancers. Across over 45 abstracts, we will share new survival data demonstrating the impact of earlier intervention with our approved therapies and the latest advancements from our innovative pipeline of next-generation therapies that have the potential to transform care for even more people living with cancer.
Read more here.
I’m energized by our presence at ESMO25 and grateful to our Pfizer Oncology team for their unwavering passion, dedication, and relentless pursuit of breakthroughs to bring new hope to people everywhere impacted by cancer.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.